1ACHC Stock Chart & Stats
€26.40
-€0.20(-0.75%)
At close: 4:00 PM EDT
€26.40
-€0.20(-0.75%)
Day’s Range― - ―
52-Week Range€6.00 - €46.00
Previous CloseN/A
Volume0.00
Average Volume (3M)38.00
Market Cap
€2.39B
Enterprise Value€5.30K
Total Cash (Recent Filing)€171.29M
Total Debt (Recent Filing)€2.56B
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Nov 04, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.45
Shares Outstanding93,100,270
10 Day Avg. Volume7
30 Day Avg. Volume38
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.39
P/FCF Ratio-2.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€28.16Price Target Upside6.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.33
Revenue Forecast (FY)€2.98B
Bulls Say, Bears Say
Bulls Say
Scale & JV Bed ExpansionMeasured capacity expansion and JVs create durable revenue runway: adding licensed beds and partnering with local health systems diversifies referral channels, accelerates facility ramp economics, and supports sustainable volume growth over multiple quarters as new beds become fully licensed and occupied.
Improving Cash Generation TrajectoryOperating cash flow improvements and a management commitment to positive free cash flow for 2026 indicate better cash conversion. Sustained OCF supports funding of CapEx, JV ramps and working capital needs without persistent external financing if trends continue over the next several quarters.
Operational Execution & Quality FocusActive cost restructuring, improved retention and quality initiatives point to lasting margin improvement potential. Ongoing efficiency measures and stronger clinical/technology focus (including pilots) should support more stable margins and referral relationships across facilities over a multimonth horizon.
Bears Say
Large Legal LiabilityA multi‑tens of millions jury award creates material legal and financial uncertainty. Potential payouts, higher reserves or insurance impacts can strain cash and profitability, distract management, and damage reputation or referral relationships, with effects that can persist through appeals and settlement timelines.
Elevated LeverageHigher leverage reduces financial flexibility for organic growth, acquisitions and to absorb shocks. With debt levels meaningfully up versus 2024, interest and covenant sensitivity rise, constraining capital allocation and increasing refinancing or liquidity risk until earnings and cash flow stabilize.
Revenue Decline & Profitability VolatilityA sizable revenue decline and sharp swing to large net losses indicate structural pressures: payer denials, specialty closures, and bad‑debt trends. Persistent volatility undermines consistent margin recovery and prolongs reliance on financing while management remedies payer and specialty segment issues.
Acadia Healthcare News
1ACHC FAQ
What was Acadia Healthcare’s price range in the past 12 months?
Acadia Healthcare lowest stock price was €6.00 and its highest was €46.00 in the past 12 months.
What is Acadia Healthcare’s market cap?
Acadia Healthcare’s market cap is €2.39B.
When is Acadia Healthcare’s upcoming earnings report date?
Acadia Healthcare’s upcoming earnings report date is Nov 04, 2026 which is in 90 days.
How were Acadia Healthcare’s earnings last quarter?
Acadia Healthcare released its earnings results on Jul 28, 2026. The company reported €0.33 earnings per share for the quarter, beating the consensus estimate of €0.3 by €0.029.
Is Acadia Healthcare overvalued?
According to Wall Street analysts Acadia Healthcare’s price is currently Undervalued.
Does Acadia Healthcare pay dividends?
Acadia Healthcare does not currently pay dividends.
What is Acadia Healthcare’s EPS estimate?
Acadia Healthcare’s EPS estimate is 0.41.
How many shares outstanding does Acadia Healthcare have?
Acadia Healthcare has 93,100,270 shares outstanding.
What happened to Acadia Healthcare’s price movement after its last earnings report?
Acadia Healthcare reported an EPS of €0.33 in its last earnings report, beating expectations of €0.3. Following the earnings report the stock price went down -13.986%.
Which hedge fund is a major shareholder of Acadia Healthcare?
Currently, no hedge funds are holding shares in IT:1ACHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acadia Healthcare Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€28.16 (6.65% Upside)
€28.16 (6.65% Upside)
Blogger Sentiment
Bullish
IT:1ACHC Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.08%
Trailing 12-Months
Company Description
Acadia Healthcare
Acadia Healthcare Company, Inc. specializes in delivering a comprehensive range of behavioral health services, with its operations spanning the United States and Puerto Rico. Patients receive care in diverse environments, including acute inpatient psychiatric hospitals, specialized treatment facilities, long-term residential centers, and outpatient clinics. As of March 31, 2022, the company managed an extensive network consisting of 238 behavioral healthcare facilities, collectively providing approximately 10,600 beds. Established in 2005, Acadia Healthcare is headquartered in Franklin, Tennessee.
1ACHC Company Deck
1ACHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive operational and financial start to 2026: revenue and adjusted EBITDA grew, results beat guidance, management raised full-year profitability targets, and execution initiatives (leadership changes, cost efficiencies, bed additions, JVs, technology) are showing early benefits. Offsetting these positives are persistent challenges in specialty (notably Pennsylvania), slower CTC performance due to weather, elevated bad debts/denials, temporary higher leverage in Q2 from timing of supplemental payments, and ongoing start-up/closure headwinds. Overall, progress on operations and margins appears to outweigh the headwinds, though some risks (payer behavior and supplemental approvals) remain.View all IT:1ACHC earnings summaries1ACHC Stock 12 Month Forecast
Average Price Target
€28.16
▲(6.65% Upside)